- In February 2025, Hope Pharmaceuticals announced the initiation of Phase III trials for its investigational sodium thiosulfate formulation, optimized for enhanced bioavailability and reduced administration time, targeting patients with ESRD-associated calciphylaxis in North America and Europe
- In October 2024, Sanifit, a Vifor Pharma company, reported positive Phase II clinical trial results for SNF472, a novel inhibitor of vascular calcification, showing improved outcomes in patients with advanced calcific uremic arteriolopathy (CUA) across U.S. and European cohorts
